Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
Your search for tofacitinib returned 95 results
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.
Pfizer announced top-line results from two Phase 3 induction trials of tofacitinib for the treatment of adults with moderate to severe ulcerative colitis (UC).
Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
A drug used for rheumatoid arthritis might regrow hair in alopecia areata (AA) patients, according to a study published online September 22 in JCI Insight.
Tofacitinib may be a viable option for patients with moderate-to-severe rheumatoid arthritis, according to a systematic review and meta-analysis reported at the 2013 ACR/ARHP Annual Meeting.
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.
Pfizer announced results from OPT Compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.